Marshall Wace, LLP A Tyr Pharma Inc Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 158,619 shares of LIFE stock, worth $247,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares

158,619

Holding current value

$247,445

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.42 - $2.02 $225,238 - $320,410	158,619 New	158,619 $309,000
Q1 2023 May 15, 2023	SELL	$1.88 - $2.5 $243,176 - $323,372	-129,349 Reduced 92.2%	10,947 $22,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $2.49 $71,940 - $88,678	-35,614 Reduced 20.25%	140,296 $307,000
Q3 2022 Nov 14, 2022	BUY	$2.79 - $4.15 $46,043 - $68,487	16,503 Added 10.35%	175,910 $527,000
Q2 2022 Aug 15, 2022	SELL	$2.63 - $5.61 $114,668 - $244,596	-43,600 Reduced 21.48%	159,407 $450,000

Q1 2022 May 16, 2022	SELL	$4.75 - $7.54 $225,097 - $357,313	-47,389 Reduced 18.93%	203,007 $1.09 Million
Q4 2021 Feb 14, 2022	BUY	$7.29 - $9.5 $1.51 Million - $1.97 Million	207,390 Added 482.24%	250,396 $1.87 Million
Q3 2021 Nov 15, 2021	BUY	$4.22 - $12.48 $181,485 - $536,714	43,006 New	43,006 $390,000

Others Institutions Holding LIFE

# of Institutions

Shares Held

33.5M

Call Options Held

7.5K

Put Options Held

3.2K

Federated Hermes, Inc. Pittsburgh, PA

10.2M
Shares

$15.9 Million
0.05% of portfolio
Logos Global Management LP San Francisco, CA

3.1M
Shares

$4.84 Million
0.56% of portfolio
Vanguard Group Inc Valley Forge, PA

2.65M
Shares

$4.14 Million
0.0% of portfolio
Tikvah Management LLC Charlotte, NC

2.46M
Shares

$3.84 Million
1.51% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

1.9M
Shares

$2.97 Million
0.0% of portfolio

View Full List

About aTYR PHARMA INC

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $44.7M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

More about LIFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account